Leerink Partners analyst Marc Goodman maintained a Buy rating on Marinus (MRNS) on March 9 and set a price target of $32.00. The company’s shares closed last Wednesday at $18.44.
According to TipRanks.com, Goodman is a 3-star analyst with an average return of 5.1% and a 48.0% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Intra-Cellular Therapies, and Satsuma Pharmaceuticals.
Currently, the analyst consensus on Marinus is a Strong Buy with an average price target of $30.50, representing a 57.1% upside. In a report issued on March 9, Oppenheimer also maintained a Buy rating on the stock with a $32.00 price target.
See today’s analyst top recommended stocks >>
Based on Marinus’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $171K and GAAP net loss of $15.66 million. In comparison, last year the company had a GAAP net loss of $15.41 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.
